Sionna Therapeutics, Inc. (SION)

NGM – Real Time Price. Currency in USD

40.94

-5.01 (-10.90%)

At close: May 12, 2026, 4:00 PM EDT

12.05.2026

Sionna Therapeutics Reports First Quarter 2026 Financial Results

Enrollment completed in the PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis; topline data on track for the summer of 2026 Ongoing Phase 1 trial evaluating NBD1 stabilizer SION-451 in proprietary dual combinations with SION-2222 and with SION-109 in healthy volunteers is also on track for topline data in the summer of 2026 Maintained strong cash position with approximately $289.9 million in cash and cash equivalents, expected to fund operations into 2028 WALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

27.04.2026

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

Topline data is on track for anticipated readout in the summer of 2026 Topline data is on track for anticipated readout in the summer of 2026

07.04.2026

Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium

WALTHAM, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in one-on-one investor meetings at the Raymond James 2026 Biotech Innovation Symposium on Tuesday, April 14th, 2026.

31.03.2026

Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another Story

Jennifer Fitzpatrick sold 10,250 shares for a total of approximately $347,000 on March 5, 2026. This transaction represented 100.00% of her direct common stock holdings, reducing direct ownership of common stock to zero.

18.03.2026

Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet?

Superstring Capital Management acquired 180,593 shares of Sionna Therapeutics in the fourth quarter. The quarter-end position value rose by $7.43 million, reflecting the purchase of a new position.

15.03.2026

This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares

OrbiMed Advisors sold 143,304 shares of Sionna Therapeutics in the fourth quarter; the estimated transaction value was $5.43 million based on quarterly average prices. Meanwhile, the quarter-end position value increased by $37.56 million, reflecting both trading and stock price movement.

02.03.2026

Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Ongoing PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis is on track with topline data anticipated in mid-2026 Ongoing Phase 1 trial evaluating NBD1 stabilizer SION-451 in proprietary dual combinations with SION-2222 and with SION-109 in healthy volunteers is on track with topline data anticipated in mid-2026 Maintained strong cash position with approximately $310.3 million in cash and cash equivalents, expected to fund operations into 2028 WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.

Videos

No Data

There is no data to display

Press releases

12.05.2026

Sionna Therapeutics Reports First Quarter 2026 Financial Results

27.04.2026

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

Topline data is on track for anticipated readout in the summer of 2026 Topline data is on track for anticipated readout in the summer of 2026

07.04.2026

Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium

02.03.2026

Sionna Therapeutics, Inc. (SION)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Sionna Therapeutics, Inc. (SION)

Sionna Therapeutics Reports First Quarter 2026 Financial Results

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium

Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another Story

Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet?

This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares

Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Videos

No Data

Press releases

Sionna Therapeutics Reports First Quarter 2026 Financial Results

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium

Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Sionna Therapeutics Reports First Quarter 2026 Financial Results

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium

Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another Story

Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet?

This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares

Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Videos

No Data

Press releases

Sionna Therapeutics Reports First Quarter 2026 Financial Results

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium

Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Search stocks

Sionna Therapeutics, Inc. (SION)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Sionna Therapeutics, Inc. (SION)

Sionna Therapeutics Reports First Quarter 2026 Financial Results

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium

Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another Story

Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet?

This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares

Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Videos

No Data

Press releases

Sionna Therapeutics Reports First Quarter 2026 Financial Results

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium

Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Sionna Therapeutics Reports First Quarter 2026 Financial Results

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium

Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another Story

Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet?

This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares

Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Videos

No Data

Press releases

Sionna Therapeutics Reports First Quarter 2026 Financial Results

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium

Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results